|Amitriptyline||Major depressive disorders and anxiety||Tablets||10, 25, 50, 75 and 100 mg|
|Amitriptyline||Major depressive disorders and anxiety||XR tablets||75 mg|
|Baclofen||Spasticity||Injection||10 mg/5 ml and 10 mg/20 ml|
|Clonazepam||Epilepsy||Tablets||0.5 mg and 2 mg|
|Duloxetine *||Major depressive disorders, neuropathic pain, anxiety||Gastro resistant hard capsules||90 and 120 mg|
|Fampridine||Multiple sclerosis||XR tablets||10 mg|
|Fingolimod||Multiple sclerosis||Capsules||0.5 mg|
|Lacosamide||Epilepsy||Oral solution||10 mg/ml|
|Methocarbamol||Muscle spasms, pain||Film-coated tablets||1.5 mg|
|Quetiapine *||Psychosis, schizophrenia, bipolar disoder||Orodispersable tablets||25 and 50 mg|
|Rotigotine||Parkinson's||Patches||1, 2, 3, 4, 6 and 8 mg/24h|
|Sodium Oxybate||Narcolepsy||Oral solution||500 mg/ml|
|Tranylcypromine||Depression||Film-coated tablets||10, 20 and 40 mg|
[*] Differentiated product
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.